Mar 17, 2023
March 16, 2023 PDF Version – Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company – – Announced CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of...
Feb 28, 2023
VANCOUVER, Wash. and NEW YORK. February 28, 2023 — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced its expansion into the European pharmaceutical market with the opening of its Innovation Center, located in Zug, Switzerland....
Nov 10, 2022
TIME’s Recognition Cements Xandar Kardian’s Status as an Industry Leader in Digital Radar Signal Processing, Empowering Automation in Digital Healthcare to Improve Quality of Care for Patients TORONTO, Nov. 10, 2022 /PRNewswire/ — Xandar Kardian, a...
Nov 9, 2022
Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a...
Nov 2, 2022
Technology veteran Dan Rabinovitsj provides expertise in collaborating with technology partners to catalyze innovation as Absci accelerates generative AI drug creation VANCOUVER, Wash. and NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq:...